Abstract

Biodegradable polymer-based injectable in situ forming depot (ISD) systems that solidify in the body to form a solid or semisolid reservoir are becoming increasingly attractive as an injectable dosage form for sustained (months to years) parenteral drug delivery. Evaluation of long-term drug release from the ISD systems during the formulation development is laborious and costly. An accelerated release method that can effectively correlate the months to years of long-term release in a short time such as days or weeks is economically needed. However, no such accelerated ISD system release method has been reported in the literature to date. The objective of the current study was to develop a short-term accelerated in vitro release method for contraceptive levonorgestrel (LNG)-containing ISD systems to screen formulations for more than 3-month contraception after a single subcutaneous injection. The LNG-containing ISD formulations were prepared by using biodegradable poly(lactide-co-glycolide) and polylactic acid polymer and solvent mixtures containing N-methyl-2-pyrrolidone and benzyl benzoate or triethyl citrate. Drug release studies were performed under real-time (long-term) conditions (PBS, pH 7.4, 37 °C) and four accelerated (short-term) conditions: (A) PBS, pH 7.4, 50 °C; (B) 25% ethanol in PBS, pH 7.4, 50 °C; (C) 25% ethanol in PBS, 2% Tween 20, pH 7.4, 50 °C; and (D) 25% ethanol in PBS, 2% Tween 20, pH 9, 50 °C. The LNG release profile, including the release mechanism under the accelerated condition D within two weeks, correlated (r2 ≥ 0.98) well with that under real-time conditions at four months.

Highlights

  • An injectable in situ forming depot/implant (ISD) system is a solution or suspension containing drug and biodegradable polymers dissolved or suspended in pharmaceutically acceptable water-miscible organic solvents, respectively [1,2,3,4,5,6]

  • Upon injection into the target tissue, the ISD forms a solid depot of polymeric matrix at the injection site because of the phase separation by solvent exchange, as the water-miscible organic solvent diffuses into the surrounding aqueous medium while the aqueous body fluid penetrates into the organic phase [3,4,7,8]

  • The biodegradable polymers will eventually completely degrade at the injection site over a period of time, and be cleared out from the body

Read more

Summary

Introduction

An injectable in situ forming depot/implant (ISD) system is a solution or suspension containing drug and biodegradable polymers dissolved or suspended in pharmaceutically acceptable water-miscible organic solvents, respectively [1,2,3,4,5,6]. Upon injection into the target tissue, the ISD forms a solid depot of polymeric matrix at the injection site because of the phase separation by solvent exchange, as the water-miscible organic solvent diffuses into the surrounding aqueous medium while the aqueous body fluid penetrates into the organic phase [3,4,7,8]. The drug entrapped in the depot is slowly released out into the surrounding body fluid due to the degradation of the polymers and diffusion of the drug, goes into the systemic circulation and reaches target sites. The ISD technology has been developed aiming at safe and Pharmaceutics 2016, 8, 28; doi:10.3390/pharmaceutics8030028 www.mdpi.com/journal/pharmaceutics

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call